| Schedule Of Accounts Receivable By Segment [Table Text Block] |
The following is a table of the Company’s net accounts receivable by segment.
| |
|
July 31, 2019 |
|
|
July 31, 2018 |
|
| Net accounts receivable by segment |
|
Amount |
|
|
% |
|
|
Amount |
|
|
% |
|
| Clinical Labs (by billing category) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Third party payers |
|
$ |
2,956 |
|
|
|
44 |
|
|
$ |
4,692 |
|
|
|
48 |
|
| Patient self-pay |
|
|
2,360 |
|
|
|
35 |
|
|
|
2,010 |
|
|
|
20 |
|
| Medicare |
|
|
910 |
|
|
|
13 |
|
|
|
1,740 |
|
|
|
18 |
|
| HMO’s |
|
|
574 |
|
|
|
8 |
|
|
|
1,329 |
|
|
|
14 |
|
| Total Clinical Labs |
|
|
6,800 |
|
|
|
100 |
% |
|
|
9,771 |
|
|
|
100 |
% |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total Life Sciences |
|
|
3,938 |
|
|
|
|
|
|
|
3,376 |
|
|
|
|
|
| Total accounts receivable – net |
|
$ |
10,738 |
|
|
|
|
|
|
$ |
13,147 |
|
|
|
|
|
|
| Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] |
The following table sets forth the computation of basic and diluted net income (loss) per share for the years ended July 31:
| |
|
2019 |
|
|
2018 |
|
|
2017 |
|
| Net income (loss) |
|
$ |
2,489 |
|
|
$ |
(10,321 |
) |
|
$ |
(2,504 |
) |
| |
|
|
|
|
|
|
|
|
|
| Weighted-average common shares outstanding - basic |
|
|
47,351 |
|
|
|
46,972 |
|
|
|
46,350 |
|
| Add: effect of dilutive stock options and restricted stock |
|
|
125 |
|
|
|
— |
|
|
|
— |
|
| Weighted-average common shares outstanding - diluted |
|
|
47,476 |
|
|
|
46,972 |
|
|
|
46,350 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Net (loss) income per share – basic |
|
$ |
0.05 |
|
|
$ |
(0.22 |
) |
|
$ |
(0.05 |
) |
| Net (loss) income per share – diluted |
|
$ |
0.05 |
|
|
$ |
(0.22 |
) |
|
$ |
(0.05 |
) |
|
| Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] |
The impact of the adoption of the standard on prior period consolidated operations, cash flows and balance sheet is presented in the table below:
|
As
Previously
Reported |
Adjustment
for New
Accounting Standard on
Revenue Recognition |
Reclassification
of Residual |
As
Restated |
Consolidated Statements of Operations for
fiscal year ended July 31, 2018: |
|
|
|
|
| Total Revenues |
$104,713 |
($3,700) |
— |
$101,013 |
| Provision for uncollectible
accounts receivable |
3,690 |
(3,700) |
$10 |
— |
| Selling, general and
administrative expenses |
44,465 |
— |
(10) |
44,455 |
| Net loss |
(10,321) |
— |
— |
(10,321) |
Consolidated Statements of Cash Flows
July 31, 2018: |
|
|
|
|
| Provision
for uncollectible accounts receivable |
3,690 |
(3,700) |
10 |
— |
Changes
in operating assets and liabilities:
Accounts receivable |
(1,775) |
3,700 |
(10) |
1,915 |
| Consolidated
balance sheet July 31, 2018: |
|
|
|
|
| Accounts
receivable |
15,815 |
(2,523) |
— |
13,292 |
| Less:
Allowance for doubtful accounts |
2,668 |
(2,523) |
— |
145 |
| Accounts
receivable, net of allowance for doubtful accounts |
13,147 |
— |
— |
13,147 |
Consolidated
Statements of Operations for
the year ended July 31, 2017: |
|
|
|
|
| Total
Revenues |
$107,804 |
($2,718) |
— |
$105,086 |
| Provision
for uncollectible accounts receivable |
2,775 |
(2,718) |
($57) |
— |
| Selling,
general and administrative expenses |
44,092 |
— |
57 |
44,149 |
| Net
loss |
(2,504) |
— |
— |
(2,504) |
Consolidated
Statements of Cash Flows
July 31, 2017: |
|
|
|
|
| Provision
for uncollectible accounts receivable |
$2,775 |
($2,718) |
($57) |
— |
Changes
in operating assets and liabilities:
Accounts receivable |
(3,244) |
2,718 |
57 |
($469) |
|